Concord Healthcare Group Issues Profit Alert: Significant Revenue and Gross Profit Growth Expected for H1 2026
Key Highlights of the Announcement
- Expected Revenue Surge: Projected revenue for the six months ended June 30, 2026 is estimated at RMB 260 million to RMB 280 million, a substantial increase from RMB 200.9 million in the same period of 2025. This reflects a year-on-year growth of approximately 29% to 39%.
- Staggering Gross Profit Growth: Gross profit is expected to reach RMB 63 million to RMB 83 million, compared to just RMB 0.38 million in the first half of 2025. This represents an extraordinary year-on-year increase of 16,349% to 21,571%.
- Main Driver: Proton Therapy Success: The growth is primarily attributed to the strong performance of the Group’s proton therapy business at Guangzhou Concord Cancer Center Co., Ltd., which has now served over 1,000 cumulative patients and surpassed 100 patients treated in a single day.
- Operational Improvements: The Group plans to continue optimizing service processes and improving diagnostic and treatment efficiency to deliver high-quality medical services to more oncology patients.
Important Information for Shareholders and Investors
- Preliminary Figures: The financial results provided are based on unaudited management accounts and are subject to adjustments. The numbers have not been reviewed or confirmed by the Company’s auditor or audit committee.
- Potential Volatility: Actual results may differ due to changes in market conditions or subsequent adjustments during the finalization of interim results.
- Interim Results Timeline: The official interim results announcement is expected by the end of August 2026.
- Shareholder Caution: Investors are urged to treat any unofficial information with caution and to be prudent when dealing in the Company’s shares, as these results could materially impact share price performance.
Board and Management
The Board of Concord Healthcare Group Co., Ltd. is led by Chairman and Executive Director Dr. YANG Jianyu. The Board comprises executive, non-executive, independent non-executive, and employee directors, reflecting strong corporate governance and oversight.
Potential Impact on Share Price
This announcement is likely to be price sensitive, given the remarkable turnaround in gross profit and sustained high revenue growth from core business operations. The scale of profitability improvement—moving from marginal gross profit to tens of millions of RMB—signals a significant positive shift in the Group’s financial health and could drive strong market interest and share price appreciation.
Disclaimer
The information above is based on the Company’s preliminary internal assessment and has not been independently audited. Investors should await the formal interim results release and exercise caution when trading the Company’s shares. This article does not constitute investment advice.
協和醫療集團發佈盈利預警：2026年上半年收入及毛利大幅增長
公告重點
- 收入大幅增長：預計2026年上半年收入約為人民幣2.6億元至2.8億元，較2025年同期的2.009億元增長約29%至39%。
- 毛利驚人增長：預計毛利約為人民幣6,300萬元至8,300萬元，而2025年同期僅為38萬元，同比增長達16,349%至21,571%。
- 主要動力——質子治療業務：業績增長主要來自集團旗下廣州協和腫瘤中心有限公司質子治療業務的強勁表現，累計服務患者超過1,000人，單日治療人數突破100人。
- 運營優化：集團將持續優化服務流程，提升診療效率，致力為更多腫瘤患者提供高質量醫療服務。
股東及投資者須知
- 數據為初步評估：有關財務數據來自未經審核的管理賬目，尚未經公司審計師或審計委員會審核，最終數據或有調整。
- 潛在波動：實際業績可能因市場變化及後續調整而與公告有所不同。
- 中期業績發布：正式中期業績公告預計於2026年8月底前公佈。
- 股東謹慎：投資者應理性對待任何非公司正式發布的信息，謹慎買賣公司股份，因公佈內容可能對股價構成重大影響。
董事會與管理層
協和醫療集團董事會由董事長及執行董事楊建宇博士領導，成員包括執行董事、非執行董事、獨立非執行董事及員工董事，顯示出公司良好的治理結構。
對股價的潛在影響
由於盈利能力顯著提升和核心業務持續高增長，該公告極具敏感性，料將對股份價格產生積極影響。毛利由微利大幅躍升至數千萬元，標誌公司財務狀況大幅改善，有望吸引市場關注並推動股價上升。
免責聲明
上述資訊基於公司內部初步評估，未經獨立審核。投資者應以正式中期業績公告為準，謹慎作出投資決定。本文不構成投資建議。
